4D Molecular Therapeutics granted four non-executive employees 23,600 Restricted Stock Units on January 13, 2026. The RSUs were granted under the Company’s 2025 Employment Inducement Award Plan to induce new employees to join. The Company is a late-stage biotech firm developing therapeutics for retinal vascular diseases and cystic fibrosis. Their lead product, 4D-150, aims to provide sustained delivery of anti-VEGF with a single injection for diseases like wet age-related macular degeneration. 4DMT’s second product candidate, 4D-710, successfully delivered the CFTR transgene in cystic fibrosis patients’ lungs. All product candidates are in clinical or preclinical stages.

Read more at GlobeNewswire: 4DMT Announces New Employment Inducement Grants